MediWound Built a Factory It Doesn't Yet Need. That's the Point.

The new manufacturing facility sits in Yavne, Israel, and it is, by the numbers, a statement of intent. When MediWound completed the expansion in 2025, the plant's production capacity for NexoBrid, the company's enzymatic debridement agent for severe burns, increased sixfold. A company does not spend years and tens of millions of dollars building capacity it does not expect to use. And yet, in the same year the facility was commissioned, MediWound's total revenue contracted to $17.0 million from $20.2 million in fiscal 2024. A factory built for growth opened its doors to a shrinking top line.

The decline was not subtle. Revenue fell 16 percent. Product sales to Vericel, MediWound's U.S. commercial partner for NexoBrid, dropped. Development services revenue, much of it tied to contracts with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense, stalled when a federal government shutdown halted work in the fourth quarter. These are not the conditions under which a company typically celebrates the opening of a major capital project. But MediWound, under Chief Executive Officer Ofer Gonen, is not operating on typical logic. The company is in the middle of what it describes as a transformation: from a single-product burn care company dependent on government contracts into a multi-indication biologics platform with a commercial engine of its own. The factory is a bet on the destination, not a reflection of the present.

Gonen's framing, delivered on the March 2026 earnings call, is the thesis in miniature. The company has placed two large bets: one on EscharEx, a new enzymatic product targeting the chronic wound market, and one on the belief that NexoBrid's commercial momentum, built across 45 countries, will eventually fill the expanded plant. The multi-year revenue guidance tells the story in numbers: $24 million to $26 million in 2026, $32 million to $35 million in 2027, and $50 million to $55 million by 2028. That top figure is nearly triple 2025's actual revenue. The guidance does not simply assume growth. It assumes a convergence of clinical success, regulatory approvals, and commercial execution that has not yet occurred.

The gap between what the company has built and what it currently earns is the central tension of the MediWound story. Every section of this profile examines one dimension of that gap: the science that created it, the government relationships that sustain it, the clinical trial that could close it, the financial arithmetic that constrains it, and the global footprint that might, eventually, justify it.

MediWound was founded in 2000 with a scientific insight that was straightforward to describe but difficult to execute: certain enzymes derived from pineapple stems, concentrated and applied as a gel, could selectively remove dead tissue from burn wounds without harming healthy skin. The process is called enzymatic debridement. In a conventional burn treatment setting, surgeons remove eschar — the dead, leathery tissue that forms after a severe burn — with scalpels, a procedure that is painful, imprecise, and requires specialized surgical facilities. An enzyme that dissolves only the dead tissue promised to shift debridement from the operating room to the bedside.

The science took years to translate into a product. NexoBrid, the company's concentrate of proteolytic enzymes enriched in bromelain, became MediWound's sole commercial asset, and it remained the only product generating meaningful revenue for most of the company's first two decades. The path from laboratory to market was incremental. The company listed on the Tel Aviv Stock Exchange and then, on March 20, 2014, completed an initial public offering on NASDAQ. Regulatory approvals accumulated gradually, jurisdiction by jurisdiction. By 2025, NexoBrid had reached 45 countries, with the Therapeutic Goods Administration in Australia granting approval for both adult and pediatric patients that same year.

But the burn care market, while medically critical, is commercially narrow. Severe burns requiring enzymatic debridement represent a limited addressable patient population. For MediWound, the burn care niche provided scientific validation and a modest revenue base — roughly $20 million a year at its peak before 2025 — but it did not provide a path to profitability or independence. The company remained dependent on development contracts with government agencies to supplement product revenue, a structure that tied its fortunes to federal budgeting cycles over which it had no control. The single-product dependency also meant that any disruption to NexoBrid supply, regulatory approvals, or commercial partner performance would hit the top line directly. The company needed a second act.

The U.S. government has been both benefactor and vulnerability for MediWound. BARDA, the agency charged with procuring medical countermeasures against chemical, biological, radiological, and nuclear threats, has funded NexoBrid development and stockpiling for years. The logic is straightforward: in a mass-casualty burn event (a terrorist attack, an industrial disaster, a military conflict), the ability to debride dozens or hundreds of burn patients quickly, without requiring a surgical team for each one, is a national security asset. The Department of Defense shares this interest. Enzymatic debridement is useful in forward-operating environments where surgical capabilities are limited, and real-world evidence gathered in military settings has reinforced the case for including NexoBrid in national stockpiles.

These relationships have provided development funding that a small-cap biotech could not easily access through commercial markets. They have also validated the technology in ways that matter for regulatory and commercial adoption. But they have introduced a structural vulnerability that became visible in the fourth quarter of 2025. When the U.S. federal government entered a shutdown, development services work funded by BARDA and Department of Defense contracts stopped. The result was immediate and material. Fourth-quarter revenue collapsed to $1.9 million, compared to $5.8 million in the same quarter of 2024.

Luxenburg's language on the March 2026 earnings call was characteristically measured. But the numbers she reported expose the concentration risk. Development services revenue, the line item most directly tied to government contracts, can disappear almost entirely when Washington stops writing checks. This is not a theoretical concern. Federal budget cycles, continuing resolutions, and shutdown threats recur with regularity. For a company that has guided investors toward $24 million to $26 million in 2026 revenue — a figure that Gonen explicitly noted assumes continued support from BARDA and the U.S. Department of War — the shutdown episode is a reminder that the growth narrative contains a dependency the company cannot control.

The government relationship is not a weakness in any strategic sense. Few small-cap biotechs have agencies of the U.S. government as paying customers. The BARDA and DoD contracts reflect genuine technological differentiation and serve a public purpose. But from an investment perspective, they make MediWound's revenue lumpy in ways that quarterly models cannot easily capture. A single political event — a budget impasse, a change in administration, a reprioritization of biodefense spending — can wipe out a quarter's development revenue without any change in the underlying value of the technology.

If NexoBrid and the BARDA relationship represent MediWound's past and present, EscharEx is the future the company is asking investors to bet on. The product applies the same enzymatic debridement mechanism that NexoBrid uses in burn care to a much larger patient population: chronic wounds. Venous leg ulcers, diabetic foot ulcers, and pressure ulcers affect millions of patients in the United States alone. Many of these wounds develop necrotic tissue that must be removed before healing can begin. The current standard of care — sharp debridement with scalpels performed by a clinician — is labor-intensive, inconsistent, and painful. An effective enzymatic alternative would compete in a market measured in billions of dollars, not the tens of millions that define the burn care niche.

The company's investment reflects the size of the opportunity. Research and development expenses surged to $14.0 million in fiscal 2025, up from $8.9 million in fiscal 2024 — a 57 percent increase driven almost entirely by the Phase III VALUE trial for EscharEx. The trial is the pivotal event in the MediWound story. Phase III trials are binary: success opens a regulatory pathway and a commercial market; failure closes both. The VALUE trial is designed to demonstrate that EscharEx is superior to a placebo gel control in achieving complete debridement of venous leg ulcers, a result that, if positive, would support a Biologics License Application (BLA) submission to the FDA.

Management has also worked to reframe the competitive landscape in EscharEx's favor. During 2025, Medicare lowered reimbursement rates for skin substitute products — a broad category of grafts, matrices, and cellular tissue products used in wound care. Gonen seized on the policy change as a structural tailwind for EscharEx.

The distinction matters. Skin substitutes have been reimbursed under a system that some policymakers viewed as overly generous, creating a market where products with varying levels of clinical evidence competed on price and distribution rather than efficacy. A biologic regulated under the BLA pathway, which requires demonstrated safety and efficacy through rigorous clinical trials, occupies a different regulatory and reimbursement category. If the VALUE trial succeeds, Gonen's argument goes, EscharEx will enter a market where competitors are facing reimbursement pressure at the same moment that MediWound can offer a product with Phase III data and a differentiated regulatory status.

The co-development partnerships the company has assembled lend institutional weight to the thesis. By early 2026, MediWound had entered research collaborations with B. Braun, Coloplast, ConvaTec, Essity, Mölnlycke, Solventum, and MiMedx — a roster of wound care companies that collectively control much of the global market. B. Braun is specifically collaborating on a planned Phase II diabetic foot ulcer study. These partnerships are not revenue-generating in the near term, and their terms are not public in detail, but they signal that established industry participants see enough scientific merit in enzymatic debridement for chronic wounds to invest resources in exploring it. The company also received positive FDA feedback on the diabetic foot ulcer program and, as of November 2025, was awaiting scientific advice from the European Medicines Agency — steps on a regulatory path that runs parallel to the venous leg ulcer indication currently in Phase III.

The financial arithmetic of MediWound's transformation is unsparing. The company ended fiscal 2025 with $53.6 million in cash and equivalents, up from $43.6 million at the end of 2024. The increase was not organic. During the year, MediWound completed a $30.0 million registered direct offering and received $3.5 million from the exercise of Series A warrants. Without those capital inflows, the cash balance would have moved in the opposite direction.

The operating loss widened to $25.3 million in fiscal 2025 from $19.4 million in fiscal 2024. Adjusted EBITDA, a metric that strips out noncash items including the warrant revaluation swings that distort net income, showed a loss of $20.3 million, worsening from $14.8 million. The company burned $5.2 million in free cash flow during the fourth quarter alone, a deepening from $3.7 million in the third quarter, as operating cash consumption and capital expenditures both rose. On a reported net income basis, the loss narrowed to $23.9 million, or $2.10 per share, from $30.2 million, or $3.30 per share, but the improvement was entirely attributable to a noncash swing in financial income related to warrant revaluation — an accounting adjustment, not an operational one.

The gross margin improvement — from 13.0 percent to 19.2 percent — is one of the few positively trending operational metrics, driven by a more favorable revenue mix. But at 19.2 percent, the margin remains thin for a biologics company, and it is not sufficient to offset the fixed costs of the expanded manufacturing facility or the escalating clinical trial expenses. The expanded plant adds depreciation and overhead to the cost structure even as production volumes remain well below capacity, a dynamic that will continue until commercial sales grow into the space.

The 2028 guidance of $50 million to $55 million in revenue, the endpoint against which Gonen is asking investors to measure the company, requires three things to happen in sequence. The VALUE trial must produce positive data. The FDA must approve EscharEx. The commercial organization must execute launches across a fragmented wound care market where established competitors and reimbursement complexity create barriers to rapid adoption. Each step carries execution risk, and the timeline leaves little room for delay. At the current quarterly cash burn rate of roughly $5 million, the $53.6 million cash balance provides approximately two and a half years of runway, enough to read out the VALUE trial but not enough to fund a full commercial launch without additional capital.

The $30 million equity raise in 2025 was necessary to maintain the balance sheet. It also diluted existing shareholders. Future raises, whether through equity, debt, or partnership monetization, would likely do the same. The company's market capitalization, even after the warrant exercises and the direct offering, reflects a valuation that assumes the EscharEx bet pays off. If it does not — if the Phase III data are negative, or if the FDA requires additional trials, or if commercial adoption falls short of the trajectory embedded in the 2028 guidance — the expanded factory in Yavne will be a monument to a future that never arrived.

Before the EscharEx thesis can be tested, there is a commercial foundation that exists today and is growing. NexoBrid is approved in 45 countries. The TGA approval in Australia in 2025, which covered both adult and pediatric patients, added another jurisdiction to a regulatory map that spans Europe, Asia, the Middle East, and the Americas. The Vericel partnership, which covers the U.S. market, has begun to show measurable traction. In the third quarter of 2025, Vericel reported record quarterly NexoBrid revenue, up 38 percent year-over-year and 26 percent sequentially — evidence that the U.S. commercial engine is building momentum after a slow initial uptake following FDA approval in late 2022.

The expanded manufacturing facility, commissioned in 2025, is now operational. The sixfold increase in capacity positions MediWound to supply not only existing commercial demand as it grows but also the potential surge in demand that would accompany national stockpiling orders from governments that view enzymatic debridement as a strategic medical countermeasure. The plant is a fixed asset on the balance sheet that will depreciate whether or not it is fully utilized, but it also removes a potential bottleneck that could have constrained growth if commercial and government demand materialized simultaneously.

Gonen frames the current position as a foundation that has been laid. The pivot from burn care to chronic wounds, the shift from government dependency to commercial sustainability, the transition from a single-product company to a platform: these are the threads he weaves together when he tells the MediWound story.

The qualifiers in that sentence — 'assumes,' 'potential,' 'subject to regulatory approval' — are the words that separate the $17 million company of 2025 from the $50 million to $55 million company of 2028. Each carries a specific risk. BARDA support is subject to federal appropriations. EscharEx's contribution is contingent on clinical trial results that have not yet been read out. Regulatory approval is the binary gate through which the entire chronic wound strategy must pass. The company has built the factory, enrolled the trial, and raised the capital. Whether the pieces converge as management projects will become clear over the next twelve to twenty-four months.

In 2025, MediWound built a factory capable of producing six times as much product as it currently sells. That decision will either look prescient or premature. The answer depends on events that have not yet occurred and data that has not yet been reported. The company has placed its bets. The next chapters will be written by clinical trial monitors, FDA reviewers, and congressional budget committees; none of whom report to Ofer Gonen.